Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | BLM | P54132 | 3/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7406980 | 1.00 | GPR17 (0.60) | GPR17KMT2AMEN1KDM4ELMNA | |
| SCHEMBL25301298 | 0.88 | KMT2A (0.53) | GPR17KMT2AMEN1KDM4ELMNA | |
| SCHEMBL25255917 | 0.88 | KMT2A (0.53) | GPR17KMT2AMEN1KDM4ELMNA | |
| SCHEMBL14432462 | 0.86 | KMT2A (0.49) | GPR17KMT2AMEN1KDM4ELMNA | |
| SCHEMBL7412910 | 0.86 | KMT2A (0.49) | GPR17KMT2AMEN1KDM4ELMNA | |
| SCHEMBL7415679 | 0.86 | KMT2A (0.49) | GPR17KMT2AMEN1KDM4ELMNA | |
| SCHEMBL9156619 | 0.83 | GPR17 (0.60) | GPR17KMT2AMEN1KDM4ELMNA | |
| SCHEMBL29655616 | 0.83 | KMT2A (0.62) | KMT2AMEN1KDM4ELMNAMAPT | |
| SCHEMBL31369891 | 0.83 | KMT2A (0.62) | KMT2AMEN1KDM4ELMNAMAPT | |
| SCHEMBL7691824 | 0.83 | KMT2A (0.62) | KMT2AMEN1KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5360814-A | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-01 | — | — | US | claimed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| US-5547991-A | NMDA antagonism method | MERRELL PHARMACEUTICALS INC. (US) | 1996-08-20 | — | — | US | disclosed |
| US-5484814-A | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5470870-A | New class of excitatory amino acid antagonist for epilepsy, anxiety or stroke | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0501378-B1 | NMDA Antagonists | MERRELL DOW PHARMA (US) | 1995-01-11 | — | — | EP | disclosed |
| US-5360814-A | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0501378-A1 | NMDA Antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | GPR17 1618/4885KMT2A 2257/4885MEN1 1615/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | GPR17 1618/4885KMT2A 2257/4885MEN1 1615/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | GPR17 1618/4885KMT2A 2257/4885MEN1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.